Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Research and Development, PeopleBio Inc., Gyeonggi-do, Republic of Korea.
J Alzheimers Dis. 2020;75(2):493-499. doi: 10.3233/JAD-200061.
Oligomeric amyloid-β (Aβ) is one of the major contributors to the pathomechanism of Alzheimer's disease (AD); Aβ oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric Aβ (MDS-OAβ) after incubation with spiked synthetic Aβ.
We evaluated the clinical sensitivity and specificity of the MDS-OAβ values for prediction of AD.
The MDS-OAβ values measured using inBlood™ OAβ test in heparin-treated plasma samples from 52 AD patients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD.
The MDS-OAβ values were 1.43±0.30 ng/ml in AD and 0.45±0.19 (p < 0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity.
MDS-OAβ to measure plasma Aβ oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.
寡聚淀粉样蛋白-β（Aβ）是阿尔茨海默病（AD）发病机制的主要因素之一；使用掺合合成 Aβ 后孵育的多聚体检测系统寡聚 Aβ（MDS-OAβ）可以测量血浆中的 Aβ 寡聚化。
我们评估了 MDS-OAβ 值对 AD 预测的临床灵敏度和特异性。
使用 InBlood™OAβ 测试在肝素处理的血浆样本中测量的 MDS-OAβ 值，与 52 名具有正常认知能力（NC）的社区对照者进行比较。纳入标准由 NINCDS-ADRDA 提出，并在 AD 病程中从初始临床诊断起至少需要 6 个月的随访。
AD 组的 MDS-OAβ 值为 1.43±0.30ng/ml，NC 组为 0.45±0.19（p<0.001）。使用 0.78ng/ml 的截断值，结果显示出 100%的灵敏度和 92.31%的特异性。
MDS-OAβ 用于测量血浆 Aβ 寡聚化是 AD 临床诊断的有价值的基于血液的生物标志物，具有高灵敏度和特异性。
